100418-51-7

Upstream product

• 1965-54-4 N-(2-hydroxyethyl)-4-nitroaniline 
• 124-63-0 methanesulfonyl chloride 
• 100-00-5 4-chlorobenzonitrile 
• 350-46-9 4-Fluoronitrobenzene 

Downstream Products

• 5464-09-5 N,N-diethyl-N'-(4-nitrophenyl)-1,2-diaminoethane 
• 863453-84-3 N-(2-pyrrolidin-1-ylethyl)benzene-1,4-diamine 
• 38519-13-0 N¹-(2-(diethylamino)ethyl)benzene-1,4-diamine 
• 1159610-53-3 C₁₆H₁₃N₃O₅ 
• 1159610-40-8 C₁₈H₁₇ClN₄O₄S 
• 1159610-75-9 C₂₆H₃₁ClN₄O₇S 
• 1159610-42-0 C₂₁H₂₁ClN₄O₄S 
• 1159610-54-4 C₈H₁₁N₃O₃ 
• 1159610-55-5 C₁₃H₁₉N₃O₅ 
• 1159610-56-6 C₁₃H₂₁N₃O₃ 
• 1159610-57-7 C₂₄H₃₀N₄O₆ 
• 1159610-58-8 C₂₅H₂₈N₄O₇ 
• 1159610-59-9 C₁₇H₂₆N₄O₅ 
• 1159610-60-2 C₂₂H₂₇ClN₄O₆S 

Relevant academic research and scientific papers

Crystal structures and density functional theory calculations of o - And p-nitroaniline derivatives: Combined effect of hydrogen bonding and aromatic interactions on dimerization energy

The interplay of strong and weak hydrogen bonds, dipole-dipole interactions, and aromatic interactions of o- and p-nitroaniline derivatives was studied by combining crystal structure analysis and density functional theory (DFT) calculations. Crystal struc

FXA INHIBITORS WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF

The present invention relates to novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group, pharmaceutically acceptable salts thereof, methods for preparing the same and pharmaceutical compositions comprising the same. The oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group or the pharmaceutically acceptable salts thereof can be effectively used for the treatment of thromboembolism and tumor as an anticoagulant based on the inhibition of factor Xa.

FXA INHIBITORS WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF

The present invention relates to novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group, pharmaceutically acceptable salts thereof, methods for preparing the same and pharmaceutical compositions comprising the same. The oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group or the pharmaceutically acceptable salts thereof can be effectively used for the treatment of thromboembolism and tumor as an anticoagulant based on the inhibition of factor Xa.

Structure-activity relationship of quinoline derivatives as potent and selective α2c-adrenoceptor antagonists

Starting from two acridine compounds identified in a high-throughput screening campaign (1 and 2, Table 1), a series of 4-aminoquinolines was synthesized and tested for their properties on the human α2- adrenoceptor subtypes (α2A, α2B, and α2C). A number of compounds with good antagonist potencies against the α2C-adrenoceptor and excellent subtype selectivities over the other two subtypes were discovered. For example, (R)-{4-[4-(3,4-dimethylpiperazin-1-yl)phenylamino]quinolin-3-yl}methanol 6j had an antagonist potency of 8.5 nM against, and a subtype selectivity of more than 200-fold for, the α2c-adrenoceptor. Investigation of the structure-activity relationship identified a number of structural features, the most critical of which was an absolute need for a substituent in the 3-position of the quinoline ring. The 3-position on the piperazine ring was also found to play an appreciable role, as substitutions in that position exerted a significant and stereospecific beneficial effect on the α2C- adrenoceptor affinity and potency. Replacing the piperazine ring proved difficult, with 1,4-diazepanes representing the only viable alternative.

Iminothiazolidine derivatives

The invention relates to novel iminothiazolidine derivatives of the formula (I), STR1 wherein R1 and R3 represent, independently from each other, hydrogen or lower alkyl group, R3 is nitro or amino group, R stands for halo, lower alkyl, haloalkyl, nitro, amino, hydroxy, lower alkoxy, carboxy or lower alkoxycarbonyl group, and n is 0, 1 or 2, and pharmaceutically acceptable acid addition salts thereof. The iminothiazolidine derivatives of the formula (I) possess valuable antidepressant, antiparkinsonic, antiepileptic and spasmolytic activities.